Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres (Q36466659)

14 August 2017

Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres (English)

1 reference

14 August 2017

multivariate statistics

1 reference

Wagstaff J

1

1 reference

14 August 2017

Gregory WM

2

1 reference

14 August 2017

Swindell R

3

1 reference

14 August 2017

Crowther D

4

1 reference

14 August 2017

Lister TA

5

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 October 1988

1 reference

British Journal of Cancer

14 August 2017

1 reference

14 August 2017

58

1 reference

14 August 2017

4

1 reference

14 August 2017

487-492

1 reference

Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

Effect of age on therapeutic response and survival in advanced Hodgkin's disease.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

30 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

30 September 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

Twenty years of MOPP therapy for Hodgkin's disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

Conclusions from clinical trials of the Southwest Oncology Group

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2246781

Immune alterations in Hodgkin's disease. Effect of delayed hypersensitivity and lymphocyte transformation on course and survival

21 September 2018

1 reference

12 December 2020

Reassessment of prognostic factors in stage IIIA and IIIB Hodgkin's disease treated with MOPP and radiotherapy

1 reference

12 December 2020

Prognostic value of serum lactic dehydrogenase level in Hodgkin's disease

1 reference

12 December 2020

Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABDV and low-dose radiation therapy restricted to originally bulky disease

1 reference

12 December 2020

Surviving Proportional Hazards

1 reference

12 December 2020

A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy

1 reference

12 December 2020

Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience

1 reference

12 December 2020

Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP

1 reference

12 December 2020

Second primary malignant neoplasms in patients treated for Hodgkin's disease at St Bartholomew's Hospital

1 reference

12 December 2020

MVPP chemotherapy regimen for advanced Hodgkin's disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1988.246

1 reference

Dimensions Publication ID

14 August 2017

0 references

1 reference

14 August 2017

PubMed publication ID

3207603

1 reference